+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • PDF Icon


  • 70 Pages
  • February 2024
  • Region: Latin America
  • Mordor Intelligence
  • ID: 5854569
The Latin America Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 754.60 million in 2024, and is expected to reach USD 931.40 million by 2029, growing at a CAGR of 4.30% during the forecast period (2024-2029).

The market is estimated to reach a value of more than USD 862 million by 2027.

The COVID-19 pandemic positively impacted the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. In the current crisis, type 2 diabetes patients are at much higher risk.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.

The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, nearly 10% of the population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, accounting for nearly 90% of the total diabetic population in 2021.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Trends

Tradjenta segment holds the highest market share in the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market in the current year

The Tradjenta segment held the highest share in the Latin America dipeptide peptidase 4 (DPP-4) inhibitors market in the current year and is expected to register a CAGR of more than 7% over the forecast period.

The Food and Drug Administration has given the prescription drug Tradjenta the go-ahead to help adults with type-2 diabetes better control their blood glucose levels. It is also used as an add-on therapy to insulin. Tradjenta should not be used in patients with type-1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).

According to the IDF Diabetes Atlas 2021, the prevalence of diabetes in Mexico reached 16.9%, or one in six adults. Additionally, 11 million adults in the country have impaired glucose tolerance, which places them at high risk of developing type-2 diabetes. Diabetes-related health expenditure in Mexico has put it in the top ten countries or territories with the highest total health expenditure. Under half of the people living with diabetes in the country are undiagnosed.

Lack of health insurance deprives the poor of access to services and puts them at risk of financial hardship. To protect the people against excessive health expenditures, many countries like Mexico have implemented mechanisms such as community-based health insurance, national health insurance, and targeted public health insurance. Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (State Employee's Social Security and Social Services Institute, ISSSTE) provides coverage for government employees, and the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS) covers private-sector employees. The Seguro Popular (People's Insurance) was launched to protect the working-age population against steep healthcare costs.

The rising prevalence and various initiatives by the Mexican government are expected to drive the market's growth.

Brazil is expected to dominate the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market over the forecast period

Brazil holds the highest market share in the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market and is also expected to register a CAGR of more than 4.7% over the forecast period.

According to the IDF Diabetes Atlas 2021, 15.7 million adults, or 10.5%, were living with diabetes in Brazil. The cost of diabetes-related health expenditures in Brazil is the third highest in the world. In addition, 18 million adults have impaired glucose tolerance, which places them at high risk of developing type-2 diabetes. Additional data on glycaemic control in Brazil show that only 25% met the therapeutic goal of glycated hemoglobin (HbA1c) less than 7% before the pandemic, as recommended by the Brazilian Diabetes Society (SBD).

Urbanization, an aging population, declining levels of physical activity, and rising rates of overweight and obesity are just a few socioeconomic, demographic, environmental, and genetic factors that are contributing to the rise in type-2 diabetes cases in Brazil. When diabetes is undetected or inadequately treated, people with diabetes are at risk of serious and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation. These result in reduced quality of life and higher healthcare costs, which lead to a greater need for access to care.

The prevalence of diabetes is growing among all ages in Brazil. Diabetes mellitus has been of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. The government has partnered with numerous private companies to utilize their supply chains to ensure low prices for drugs. Brazil has implemented a set of reforms over the past decade to improve the distribution of doctors, develop new forms of service organization, introduce new financing models, and implement a range of quality improvement initiatives and policy frameworks to overcome risk factors such as obesity and emerging pandemic threats.

Owing to the factors mentioned above, the market is likely to grow over the forecast period.

Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Overview

The Latin America dipeptide peptidase 4 (DPP-4) inhibitors market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Merck, Boehringer Ingelheim, and Novartis gaining presence in major countries while the remaining market comprises other local or region-specific manufacturers.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5.1 Drugs
5.1.1 Januvia (Sitagliptin)
5.1.2 Onglyza (Saxagliptin)
5.1.3 Tradjenta (Linagliptin)
5.1.4 Vipidia/Nesina (Alogliptin)
5.1.5 Galvus (Vildagliptin)
5.1.6 Other Drugs
5.2 Geography
5.2.1 Mexico
5.2.2 Brazil
5.2.3 Rest of Latin America
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7.1 Company Profiles
7.1.1 Merck And Co.
7.1.2 AstraZeneca
7.1.3 Bristol Myers Squibb
7.1.4 Novartis
7.1.5 Takeda Pharmaceuticals
7.1.6 Eli Lilly
7.1.7 Boehringer Ingelheim
7.2 Company Share Analysis
7.2.1 AstraZeneca
7.2.2 Eli Lilly
7.2.3 Boehringer Ingelheim
7.2.4 Other Company Share Analyses

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck And Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Takeda Pharmaceuticals
  • Eli Lilly
  • Boehringer Ingelheim